CHD7

Across TCGA pan-cancer cohorts, CHD7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHD7 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CHD7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHD7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

KIRC, UCEC, and ACC are the cancer types where CHD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.623	0.876	.001	42	view →
UCEC	OS	Median	II,III,IV	0.924	0.309	.002	34	view →
ACC	OS	Median	All	0.132	0.640	<.001	28	view →
BLCA	OS	Median	II,III,IV	0.862	0.701	.021	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	6	view →
SKCM	DFS	Median	All	0.477	0.624	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHD7–KIRC (OS)

Open the KIRC breakdown →